2191
vs
N
Nikkei 225
2191
Over the past 12 months, Tella Inc has underperformed Nikkei 225, delivering a return of 0% compared to the Nikkei 225's +37% growth.
Stocks Performance
2191 vs Nikkei 225
Performance Gap
2191 vs Nikkei 225
Performance By Year
2191 vs Nikkei 225
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tella Inc
Glance View
tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. The company is headquartered in Shinjuku, Tokyo-To and currently employs 30 full-time employees. The company went IPO on 2009-03-26. The firm operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.
